Physician profile
Eileen Wang
NPI 1710290192
$273,989.26
in general payments reported to CMS, 2019-2025
13 companies · $161K in 2025
The $161K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $2,134 · 2021: $9,072 · 2022: $7,272 · 2023: $40K · 2024: $53K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $164K · Travel and Lodging: $30K · Consulting Fee: $29K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Food and Beverage: $6,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $164,175.00 |
| Travel and Lodging | $29,708.97 |
| Consulting Fee | $28,652.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,000.00 |
| Food and Beverage | $6,480.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $195,700.94 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $42,741.03 | 2019-2025 | Nucala |
| Amgen INC. | $16,775.39 | 2021-2024 | Tezspire |
| Genentech USA, INC. | $11,007.05 | 2022-2023 | Xolair |
| Astrazeneca Uk Limited | $7,372.01 | 2019-2024 | Tezspire |
| Abbott Laboratories | $151.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $111.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $86.84 | 2023 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $25.75 | 2025 | Dupixent |
| Optinose US, INC. | $17.10 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.